Key Highlights

  • Third-quarter Operating Income excluding special items fell 6% at constant currency at Fresenius Medical Care (NYSE:FMS), a decline the company tied to expected changes in TDAPA reimbursement.
  • Full-year 2026 operating income growth is now expected to be flat to a negative mid-single-digit rate, narrowed to the lower half of the prior guidance range.
  • EUR 357 million had gone toward the second EUR 1 billion share buyback by September 30, 2026, covering 9.1 million shares, or 3.4% of share capital.
  • EUR 74 million of sustainable savings came from the FME25+ transformation during the quarter, set against EUR 54 million of one-time costs.

A New CEO Trims the Profit Forecast

Fresenius Medical Care (NYSE:FMS) held its third quarter 2026 call on November 3, 2026, the first led by new CEO Shervin Korangy, who took over three weeks earlier after sitting on the Supervisory Board since December 2023. Group Revenue held roughly steady, while operating income excluding special items declined 6% at constant currency, producing an Operating Margin of 11%. Management now projects flat to negative mid-single-digit operating income growth for 2026, the lower half of earlier guidance, while still expecting broadly flat constant currency revenue. A fuller 2027 outlook is due with full-year results in February.

TDAPA Headwinds, Rising Inflation and Divergent Segments

TDAPA is a temporary Medicare add-on payment for new dialysis drugs. Management said its effect has swung from tailwind to headwind, with more pressure arriving in the fourth quarter as the phosphate binder window closes. Inflation, fueled by oil and gas costs and logistics expenses linked to Middle East tensions, is now forecast to exceed the top of the original EUR 300 million range. Care Delivery revenue grew 1% at constant currency and its margin expanded to 14.7%, but U.S. same-market treatment growth dipped 1.1%. Value-Based Care revenue fell 9% after a contract changed its risk structure, yet operating income moved up to EUR 1 million from a EUR 21 million loss. Care Enablement revenue rose 5%, aided by sales of the 5008X machine.

FDA Audit Follow-Up, Special Charges and the Buyback Schedule

Special items netted to a EUR 161 million cost, including China strategy expenses tied to ending 4008A production and exiting peritoneal dialysis. Korangy also noted that recent FDA inspections of company facilities led to corrective and preventive actions, a Regulatory Risk the call did not quantify. Operating Cash Flow grew 8%, net Debt including Lease liabilities rose 6% and net Leverage held at 2.6x, near the bottom of a 2.5x to 3x target. The first Tranche of the buyback, up to EUR 600 million, is about 60% complete and should finish by mid-December. By September 30, 348 clinics, or 14% of the total, had moved to the 5008X system, against a goal of 20% of the installed base by year end.

Where Things Stand

Fresenius Medical Care (NYSE:FMS) lowered its profit outlook because temporary reimbursement support is fading, inflation is running above plan and U.S. treatment volumes are still recovering, while steady revenue and cost savings are not fully offsetting those pressures. The evidence is mixed: Care Delivery margin and cash generation improved and leverage is steady, yet operating income fell and the lower half of guidance is now the working assumption. Investors will watch the fourth quarter TDAPA impact, U.S. patient volumes, FDA remediation progress and the February 2027 outlook.